Skip to main content
Clinical Trials/JPRN-UMIN000016794
JPRN-UMIN000016794
Completed
Phase 2

Phase II trial of treatment based on gene profiling diagnosis using next generation sequencing for carcinoma of unknown primary site - Phase II trial of treatment strategy using NGS for carcinoma of unknown primary

Ministry of Health, Labour and Welfare scientific research Nakagawa squad0 sites110 target enrollmentMarch 13, 2015

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
ntreated Carcinoma of Unknown Primary Site
Sponsor
Ministry of Health, Labour and Welfare scientific research Nakagawa squad
Enrollment
110
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2015
End Date
January 31, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ministry of Health, Labour and Welfare scientific research Nakagawa squad

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Patients with the specific sub groups are not eligible: (2\)Patients with uncontrolled brain metastases and all patients with meningeal metastases. (3\)Women who are pregnant or lactating. drug within 28 days of starting treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector - EBGraftThe trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL7A1 cDNA.MedDRA version: 20.0 Level: LLT Classification code 10074980 Term: Epidermolysis bullosa aquisita System Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2016-002790-35-FRINSERM3
Completed
Phase 1
Phase I/II clinical trial of biologic therapy with intratumoral TG1042 (Adenovirus-Interferon-gamma) in patients with Advanced Cutaneous T-Cell Lymphomas (CTCL) - Mycosis Fungoides and other CTCL - and multilesional Cutaneous B-Cell Lymphomas (CBCL)C84C84.0C85.1Mature T/NK-cell lymphomasMycosis fungoidesB-cell lymphoma, unspecified
DRKS00000219Transgene39
Active, not recruiting
Phase 1
Clinical trial to evaluate the effect of vitamin D on renal progression in patients with Chronic Kidney Disease and vitamin D deficiency
EUCTR2016-002913-23-ESFundación Hospital Alcorcón170
Active, not recruiting
Phase 1
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-004537-25-FRCentre Léon Bérard25
Active, not recruiting
Phase 1
Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphismsMetastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-001508-45-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)100